Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NYG5
UPID:
APC11_HUMAN
Alternative names:
Cyclosome subunit 11; Hepatocellular carcinoma-associated RING finger protein
Alternative UPACC:
Q9NYG5; A8MTT2; B7ZW64; Q502X9; Q9BW64; Q9P0R2
Background:
Anaphase-promoting complex subunit 11, also known as Cyclosome subunit 11 or Hepatocellular carcinoma-associated RING finger protein, plays a pivotal role in cell cycle regulation. It forms a crucial part of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase. This complex is instrumental in controlling progression through mitosis and the G1 phase by mediating ubiquitination and subsequent degradation of target proteins. It primarily facilitates the formation of 'Lys-11'-linked polyubiquitin chains, with lesser activity towards 'Lys-48'- and 'Lys-63'-linked chains.
Therapeutic significance:
Understanding the role of Anaphase-promoting complex subunit 11 could open doors to potential therapeutic strategies.